Patient-Reported Outcomes Are Key To Understanding Success of Bundled Payments – NPC’s Dubois
This article was originally published in The Pink Sheet Daily
Experience with the end-stage renal disease prospective payment system reveals a valuable lesson – that patient-related quality metrics are needed to fully assess the impact the system has on the patient, something that will be valuable when bundling is considered for treatments where drug costs are significant.
You may also be interested in...
GAO Tracks Decline In ESA Use Following Regulatory Changes
A Government Accountability Office report finds that use of erthryopoiesis-stimulating agents in dialysis decreased 31% from 2007 to the end of 2011 after Medicare’s bundled dialysis payment was changed to include drugs and FDA revised dosing recommendations.
Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen
Although manufacturers and other stakeholders were unable to convince CMS to change its stance on including oral-only drugs to treat end-stage renal disease in a new prospective payment system, the agency's decision to delay that step for three years is being viewed as a somewhat positive result for Amgen and Genzyme in the short term
ESRD Bundling Debate Shifts To Congress With Receipt Of CMS Report
Congress will start looking at the specifics of how to bundle payment for a variety of services related to end-stage renal disease treatment, now that CMS has issued a report on the subject